Drug interactions
Mavacamten + Nilutamide
Severity: Major
Mavacamten and Nilutamide: major interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Nilutamide inhibits CYP2C19, which is the main enzyme clearing mavacamten. Higher mavacamten exposure can reduce ejection fraction excessively and risk heart failure.
What this interaction means in plain words
Mavacamten and Nilutamide can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.
Mavacamten belongs to Cardiovascular; Nilutamide belongs to Endocrine.
Why it happens
Nilutamide inhibits CYP2C19, reducing mavacamten metabolism and increasing its exposure.
What to do
Monitor left ventricular ejection fraction and clinical status closely when nilutamide is started or stopped. Adjust the mavacamten dose per labeling and echocardiographic findings.
What to ask your pharmacist
- Does the benefit of taking both outweigh the risk in my case?
- Do I need any blood test, ECG or other check while on both?
- What early warning signs should I watch for, and what should I do if they appear?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Mavacamten and Nilutamide, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Nilutamide
Other interactions of Mavacamten
- Apalutamide + Mavacamten Contraindicated
- Carbamazepine + Mavacamten Contraindicated
- Clarithromycin + Mavacamten Contraindicated
- Dexlansoprazole + Mavacamten Contraindicated
- Efavirenz + Mavacamten Contraindicated
- Enzalutamide + Mavacamten Contraindicated
Frequently asked questions
Can I take Mavacamten with Nilutamide?
MediHelp rates the interaction as major. Mavacamten and Nilutamide can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Nilutamide inhibits CYP2C19, which is the main enzyme clearing mavacamten. Higher mavacamten exposure can reduce ejection fraction excessively and risk heart failure.
How serious is the interaction between Mavacamten and Nilutamide?
MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor left ventricular ejection fraction and clinical status closely when nilutamide is started or stopped. Adjust the mavacamten dose per labeling and echocardiographic findings.
What other medicines interact with Nilutamide?
MediHelp also lists interactions of Nilutamide with, for example, Dihydroergotamine intranasal, Artemether / lumefantrine, Erythromycin base. The full list is on the Nilutamide page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
